Aequus Pharmaceuticals Inc (AQS) - Total Liabilities
Based on the latest financial reports, Aequus Pharmaceuticals Inc (AQS) has total liabilities worth CA$7.09 Million CAD (≈ $5.13 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Aequus Pharmaceuticals Inc to assess how effectively this company generates cash.
Aequus Pharmaceuticals Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Aequus Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check Aequus Pharmaceuticals Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Aequus Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Aequus Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Upsellon Brands Holdings Ltd
TA:CHR
|
Israel | ILA2.01 Million |
|
Craven House Capital PLC
LSE:CRV
|
UK | $1.93 Million |
|
Foncière 7 investissement Société Anonyme
PA:LEBL
|
France | €57.45K |
|
CML Microsystems Plc
LSE:CML
|
UK | GBX14.82 Million |
|
Time Out Group plc
LSE:TMO
|
UK | GBX110.88 Million |
|
Gelion PLC
LSE:GELN
|
UK | GBX1.54 Million |
|
Time Finance PLC
LSE:TIME
|
UK | GBX170.01 Million |
|
TCTM Kids IT Education Inc.
NASDAQ:VSA
|
USA | $1.83 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Aequus Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Aequus Pharmaceuticals Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 36.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aequus Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aequus Pharmaceuticals Inc (2013–2024)
The table below shows the annual total liabilities of Aequus Pharmaceuticals Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$7.26 Million ≈ $5.25 Million |
+34.85% |
| 2023-12-31 | CA$5.38 Million ≈ $3.89 Million |
+75.16% |
| 2022-12-31 | CA$3.07 Million ≈ $2.22 Million |
+20.03% |
| 2021-12-31 | CA$2.56 Million ≈ $1.85 Million |
-0.07% |
| 2020-12-31 | CA$2.56 Million ≈ $1.85 Million |
+0.43% |
| 2019-12-31 | CA$2.55 Million ≈ $1.84 Million |
+709.71% |
| 2018-12-31 | CA$314.90K ≈ $227.79K |
-14.16% |
| 2017-12-31 | CA$366.84K ≈ $265.36K |
-50.72% |
| 2016-12-31 | CA$744.41K ≈ $538.50K |
-34.99% |
| 2015-12-31 | CA$1.15 Million ≈ $828.33K |
+53.80% |
| 2014-12-31 | CA$744.51K ≈ $538.56K |
+1212.23% |
| 2013-12-31 | CA$56.74K ≈ $41.04K |
-- |
About Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceu… Read more